Inhaled corticosteroids are an established treatment for asthma. Their success is based on their ability to improve control of asthma, to allow the reduction of other drugs, such as oral corticosteroids, and perhaps to limit the risk of long term decline in lung function. These impressive advantages are achieved with a few common unwanted effects, such as oral candidiasis and dysphonia, which are relatively trivial, more serious side effects occurring only towards the top of the recommended dose range.
Not surprisingly, this good risk: benefit record has led to a steadily growing number of prescriptions, but also to carelessness in doctors' atttitudes. Inhaled corticosteroids are usually prescribed by number ofpuffs rather than actual dose and are often spoken of as "high dose" or "low dose" in a way that does not occur with other medication.
Systemic side effects do undoubtedly occur at doses above 1 mg/day but these may be an acceptable risk in a patient who would otherwise have to take oral corticosteroids. Precise knowledge of the true benefits and risks of inhaled corticosteroids at different doses is hard to come by and dose-response curves for wanted and unwanted effects are not well established. The aim of this article is to review the published evidence relating the dose of inhaled corticosteroids to benefits and risks, both to aid rational prescribing and to draw attention to the rather large gaps in our knowledge.
Benefits
The benefits of inhaled corticosteroids were first suggested by their basic pharmacological properties and then established by clinical trials. These trials were originally designed to find out whether inhaled corticosteroids could replace oral corticosteroids. Nowadays inhaled corticosteroids are usually started as the first form of steroid treatment and so the early trials are not as relevant as they were and fail to answer many of today's questions.
PHARMACOLOGY
The most important properties of all inhaled corticosteroids are high topical potency, usually established in animal models of uncertain relevance to human asthma, combined with low systemic bioavailability.' On these grounds alone beclomethasone dipropionate and budesonide show major advantages over oral corticosteroids such as prednisolone, and theory has been borne out The results suggest better lung function and asthma control with increasing dose of inhaled corticosteroids and show no plateau on the dose-response curve. An important additional finding was that the dose-response curves were different for different measures of response-for example, flow rates do not respond in the same way as disability.
Smith and Hodson" reported experience with the "high dose" beclomethasone dipropionate inhaler (250 pg/puff) in 293 patients whose dose had been increased either because of poor asthma control or because of the continuing need to take oral corticosteroids. This allowed a comparison between "standard" (400 dg/day) and "high" doses (500-2000 Mg/day) and showed a benefit from the latter, though most of the "high dose" patients took only 1000 ug/day. Recently, in an open trial, nebulised budesonide 4-8 mg/day allowed 14 patients who had taken at least 7-5 mg/day of prednisolone for two years or more to stop and also resulted in slight improvement in asthma control.'2 Part of the benefit of such high doses may be systemic steroid replacement in patients with adrenal suppression from long term steroids.
Two studies have compared inhaled with oral corticosteroids in relatively small groups of patients. In the first study patients taking regular oral steroids were asked to In contrast, minor differences favouring budesonide have been found in children. Bisgaard3" showed that urinary free cortisol excretion fell when beclomethasone dipropionate dose rose from 200 to 800 pg/day, whereas this did not apply to budesonide. Pedersen39 showed that urinary free cortisol excretion was unequivocally higher in children taking budesonide than in those taking beclomethasone dipropionate. In both of these studies, however, the differences were small and of doubtful clinical importance.
Bone metabolism There is suggestive evidence that inhaled corticosteroids can play a part in the development of osteoporosis. This evidence comes both from short term studies of bone metabolism in normal subjects (table 2) and from bone density measurements in patients with asthma (table 3) . The short term studies can be criticised as they only predict that osteoporosis is likely to occur with long term use but do not prove that it actually does. The studies in asthmatic patients can be criticised as oral corticosteroids has always been taken previously and so may be, at least in part, responsible for the changes; such a study, by Packe et al,S3 is reported in this issue of Thorax (p415). Furthermore, the relation between low bone density and clinical events is uncertain and so the true importance of the reported changes is still not known. Nevertheless, the fact that changes can be detected with 400 pg/day and increase with dose strongly suggests that clinical problems will occur in Topical changes Dysphonia Some change in the quality ofthe voice is quite common with inhaled corticosteroids and usually does not matter.7172 It can, however be a disabling side effect for singers and others who live by their voice. The effect is dose related and can be minimised by using spacer devices and techniques that limit oropharyngeal deposition of the drug. Slow inhalation, use of a spacer device, and gargling all limit the dysphonia.
Candidiasis Positive throat swabs are common in the normal population (20-30%) and as frequent as 40% in patients taking inhaled corticosteroids. Symptomatic candidiasis, however, affects less than 5% and can usually be controlled by a combination of measures to limit oropharyngeal deposition and, in some cases, topical antifungal treatment.7374 
